These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6949460)

  • 21. Immediate and sustained haemodynamic effects of prazosin during upright exercise in man.
    Silke B; Hendry WG; Taylor SH
    Br Heart J; 1981 Dec; 46(6):663-70. PubMed ID: 7317235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Importance of neuroendocrine regulators of vascular tone and integral adrenoreceptor interaction during oral vasodilator therapy of severe congestive heart failure with prazosin.
    Awan NA; Beattie JM; Evenson ME; Needham KE; Mason DT
    J Cardiovasc Pharmacol; 1982; 4 Suppl 1():S176-80. PubMed ID: 6175836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of refractory congestive heart failure with prazosin.
    Awan NA; Evenson MK; Needham KE; Mason DT
    Am Heart J; 1981 Sep; 102(3 Pt 2):626-34. PubMed ID: 6267922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prazosin in the treatment of chronic cardiac insufficiency].
    Champoud O; Cribier A; Letac B
    Ann Med Interne (Paris); 1985; 136(3):261-5. PubMed ID: 2862824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can prazosin be used in the treatment of refractory heart failure only on the basis of clinical monitoring?
    Nikolić V; Planinc D; Rudar M; Pagon L
    Wien Med Wochenschr; 1987 Jan; 137(1):9-13. PubMed ID: 3590814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure.
    Chatterjee K; Ports TA; Arnold S; Brundage B; Parmley W
    Br Heart J; 1979 Dec; 42(6):657-63. PubMed ID: 534582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute hemodynamic and long-term clinical effects of prazosin in the treatment of chronic congestive heart failure.
    von der Lippe G; Ohm OJ; Lund-Johansen P
    Acta Med Scand; 1981; 210(3):213-6. PubMed ID: 7293839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of pharmacodynamic tolerance to prozosin in congestive heart failure.
    Desch CE; Magorien RD; Triffon DW; Blanford MF; Unverferth DV; Leier CV
    Am J Cardiol; 1979 Nov; 44(6):1178-82. PubMed ID: 495512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative hemodynamic effects of intravenous nitroprusside and oral prazosin in refractory heart failure.
    Mehta J; Iacona M; Feldman RL; Pepine CJ; Conti CR
    Am J Cardiol; 1978 May; 41(5):925-30. PubMed ID: 645603
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect of prazosin in therapy-resistant chronic cardiac failure (author's transl)].
    Lemke R; Trompler A; Kaltenbach M; Bussmann WD
    Dtsch Med Wochenschr; 1979 Dec; 104(50):1769-73. PubMed ID: 510213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure.
    Mason DT
    Am J Med; 1978 Jul; 65(1):106-25. PubMed ID: 99030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy.
    Laslett LJ; DeMaria AN; Amsterdam EA; Mason DT
    Arch Intern Med; 1978 May; 138(5):819-20. PubMed ID: 646547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of ibopamine plus prazosin in congestive heart failure.
    Naidoo DP; Rocke A; Mitha AS
    S Afr Med J; 1998 Feb; 88 Suppl 1():C25-31. PubMed ID: 9542492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study.
    Markham RV; Corbett JR; Gilmore A; Pettinger WA; Firth BG
    Am J Cardiol; 1983 May; 51(8):1346-52. PubMed ID: 6342353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year].
    Reifart N; Schmidt-Moritz AD; Nadj M; Kaltenbach M; Bussmann WD
    Z Kardiol; 1985 Apr; 74(4):205-12. PubMed ID: 3923726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin.
    Miller RR; Awan NA; Maxwell KS; Mason DT
    N Engl J Med; 1977 Aug; 297(6):303-7. PubMed ID: 889599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy.
    Awan NA; Lee G; DeMaria AN; Mason DT
    Am Heart J; 1981 May; 101(5):541-7. PubMed ID: 7223594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effects of prazosin, SGB-1534, dobutamine and isoproterenol on congestive heart failure in dogs].
    Sonoki H; Uchida Y; Tomaru T; Sugimoto T
    Nihon Yakurigaku Zasshi; 1988 Aug; 92(2):119-26. PubMed ID: 2906315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Long-term therapy with oral prazosin in chronic congestive heart failure: a clinical and echocardiographic evaluation (author's transl)].
    Sparvieri F; Cesari GP; Soro A
    G Ital Cardiol; 1980; 10(6):730-40. PubMed ID: 6780400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydralazine in chronic CHF.
    Chatterjee K; Rouleau JL; Massie BM
    Acta Med Scand Suppl; 1981; 652():99-113. PubMed ID: 6949469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.